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Epidemiological data on the occurrence of cancer in sub-Saharan Africa are sparse, and population-based cancer survival data are
even more difficult to obtain due to various logistic difficulties. The population-based Cancer Registry of Kampala, Uganda, has
followed up the vital status of all registered cancer patients with one of the 14 most common forms of cancer, who were diagnosed
and registered between 1993 and 1997 in the study area. We report 5-year absolute and relative survival estimates of the Ugandan
patients and compare them with those of black American patients diagnosed in the same years and included in the SEER Program of
the United States. In general, the prognosis of cancer patients in Uganda was very poor. Differences in survival between the two
patient populations were particularly dramatic for those cancer types for which early diagnosis and effective treatment is possible. For
example, 5-year relative survival was as low as 8.3% for colorectal cancer and 17.7% for cervical cancer in Uganda, compared with
54.2 and 63.9%, respectively, for black American patients. The collection of good-quality follow-up data was possible in the African
environment. The very poor prognosis of Ugandan patients is most likely explained by the lack of access to early diagnosis and
treatment options in the country. On the policy level, the results underscore the importance of the consistent application of the
national cancer control programme guidelines as outlined by the World Health Organization.
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Although cancer registries have been present in sub-Saharan
Africa for 50 years, they are few, and population-based epidemio-
logical cancer data are sparse. From the region, population-based
cancer survival estimates for many different cancers were only
reported once before, and two further studies restricted to cervical
cancer already make the list of population-based cancer survival
reports complete (Wabinga et al 2003; Chokunonga et al, 2004;
Gondos et al, 2004). This paper provides survival estimates of
patients diagnosed with one of the 14 most common cancers in
Kampala, Uganda, 1993–1997. We present 5-year absolute and
relative survival estimates, and we compare the results with those
of black American cancer patients diagnosed in the same period
and registered in the Surveillance, Epidemiology and End Results
(SEER) programme of the National Cancer Institute of the United
States (SEER, 2002).
METHODS
Database
This study is based on data of the Kampala Cancer Registry
(Kampala, Uganda), which was established in 1951 and is one of
the longest standing cancer registries on the African continent. The
registry covers the area of Kyadondo county, which comprises
Kampala, the capital city of Uganda and neighbouring urban and
semiurban areas, with an estimated total population of 1.2 million
(1998). Although registry operations were massively influenced by
the political turmoil after 1971 and were actually stopped between
1980 and 1989, the functioning has been undisturbed since the
reopening of registration in 1989.
Cancer incidence data from the registry have been published in
detail, describing the changes across several decades and into the
era of AIDS (Wabinga et al, 1993, 2000; Parkin et al, 1999). In the
1990s, the cancers with the highest incidence were Kaposi sarcoma,
prostate cancer, and oesophageal cancer among men and cervical
cancer, breast cancer, and Kaposi sarcoma among women
(Wabinga et al, 2000). With the AIDS epidemic, large increases
in the incidence of Kaposi sarcoma, squamous cell carcinoma of
the conjunctiva, and non-Hodgkin’s lymphoma have been
observed (Parkin et al, 1999). The registry is one of the African
registries taking part in an international effort to assess cancer
occurrence and management in developing countries. The project
is coordinated by the International Agency of Research on Cancer
(IARC, Lyons/France).
The registry methods and results have been described previously
(Wabinga et al, 1993, 2000). Case finding is conducted by active
search for newly diagnosed cases identified from the records of
three pathology laboratories and six hospitals in the area and from
the Uganda Hospice. Death certificates are rarely completed for
deaths occurring outside hospital, and are therefore not used as a
source of information. The completeness of registration was
assessed during the mid-1990s and was found to be around 90%
for incident cases (Parkin et al, 2001).
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cancers reported to the Kampala Cancer Registry between 1993
and 1997, except for Kaposi sarcoma (in total 1376 patients
between 1993 and 1997), of whom only patients with a known HIV
status were included (N¼249). Most of these patients participated
in a recent case–control study of HIV and cancer in the area
(Ziegler et al, 1997).
The follow-up was carried out from January 2001 to June 2002,
the effective cutoff date for the follow-up of patients’ vital status
was 31 December 1999. The process of follow-up posed a serious
challenge to the registry, as medical or civil death certification is
not performed routinely in the country (Wabinga et al, 2003).
Therefore, if institutional records did not provide sufficient
information on the vital status of the patient, home visits were
undertaken. These were often extremely difficult to carry out, as
street addresses are not used, and residence is defined simply as
the village or city area. Consequently, despite enormous efforts by
the registry, many patients could not be fully traced for the entire
follow-up period. These patients with incomplete follow-up were
included in the analysis, and were censored alive in the month in
which they were last seen.
Statistical analysis
For each cancer site, absolute (observed) and relative survival
estimates were calculated. Relative survival figures quantify net
(cancer-related) survival, and they are obtained as the ratios of
absolute (observed) survival and the expected survival in the
absence of cancer (Ederer et al, 1961). The latter was determined
from age and sex-specific WHO life table estimates for Uganda,
which were calculated for the year 2000 and are based on
approximated model calculations, since vital statistics are not
available (Lopez et al, 2001). These population life tables represent
the survival experience of the entire Ugandan population and take
the AIDS epidemic into account. Calculations of relative survival
were performed according to Hakulinen’s method (Hakulinen,
1982), using the SAS macro periodh (Brenner et al, 2002). Stand-
ard errors of survival estimates were calculated according to
Greenwood’s (1926) method.
Absolute and relative 5-year survival estimates for Ugandan
patients were compared with the corresponding estimates for black
patients diagnosed in the same years in the United States. For the
black American patients, data from the cancer registries included
in the SEER programme were used, a data source renowned for its
high quality in all aspects of cancer registration. Owing to the large
age differences between the Ugandan and the SEER cancer
populations, the estimates for black American patients were
adjusted to the age distributions of the Ugandan patients using
three broad age groups (o30, 30–59, and X60). The adjustment
of relative survival estimates was performed as described by
Brenner and Hakulinen (2003).
RESULTS
Overall, 2337 patients were diagnosed with cancer and reported to
the Kampala cancer registry between 1993 and 1997. Out of these,
506 (21.7%) patients were excluded from the analysis because there
was no information on their vital status after diagnosis or they had
other critical data missing that was required for the analysis.
Table 1 describes the cancer patient population included in the
survival analysis. Among patients who were included in the
analysis, 26.8% were lost at some point during the follow-up and
could not be fully traced until death or the cutoff date. The
proportion of histologically verified cases was 61.8% overall, with a
maximum of 83.2% for patients with Kaposi sarcoma, and a
minimum of 33.3% for patients with liver cancer.
Table 1 Cancer patients included in the survival analysis in Kampala,
Uganda, 1993–1997
Cancer site No.
a
Patients with
complete
data
Patients lost
to follow-up
(%)
Histologically
verified (%)
Nasopharynx 50 31 19 (30.2) 78.0
Oesophagus 182 151 31 (15.8) 39.6
Stomach 91 67 24 (23.1) 48.4
Colorectal 104 81 23 (20.0) 60.6
Liver 117 101 16 (12.0) 33.3
Lung 50 41 9 (16.4) 62.0
Breast 174 96 78 (33.5) 63.2
Cervix uteri 285 149 136 (29.6) 63.9
Ovary 69 48 21 (28.0) 52.2
Prostate 161 119 42 (19.7) 72.7
Eye 88 39 49 (35.0) 72.7
Thyroid 41 20 21 (41.2) 80.5
Lymphomas 199 117 82 (32.7) 79.4
Kaposi sarcoma 220 145 75 (30.1) 83.2
Total 1831 1205 626 (26.8) 61.8
aExcluding patients with missing/invalid data or no follow-up after diagnosis.
Table 2 Median age of cancer patients in Kampala, Uganda, compared
with patients from the United States, 1993–1997
Cancer site Uganda
USA Black
American patients
Nasopharynx 32 50
Oesophagus 58 63
Stomach 55 68
Colorectal 53.5 67
Liver 42 62
Lung 48 65
Breast 45 56
Cervix 43 49
Ovary 40 61
Prostate 70 68
Eye 28 2
Thyroid 46 45
Lymphomas 10 46
Kaposi Sarcoma HIV+ (N¼188) 30 —
Kaposi Sarcoma HIV  (N¼32) 29
Table 3 Absolute and relative survival (in %) of Ugandan patients with
cancer, Kampala, Uganda, 1993–1997
Cancer site
5-year absolute
survival s.e.
a
5-year relative
survival s.e.
Nasopharynx 0.0 — 0.0 —
Oesophagus 3.5 1.8 4.5 2.3
Stomach 0.0 — 0.0 —
Colorectal 6.6 3.1 8.3 3.9
Liver 2.7 1.9 3.2 2.2
Lung 0.0 — 0.0 —
Breast 38.4 6.0 45.4 7.1
Cervix 15.9 4.2 18.2 4.8
Ovary 14.1 7.0 16.2 8.1
Prostate 29.5 4.8 46.9 7.7
Eye 31.3 9.0 34.2 9.8
Thyroid 11.8 10.0 13.4 11.4
Lymphomas 33.4 5.5 35.4 5.8
Kaposi sarcoma
HIV+
8.2 3.2 9.1 3.6
Kaposi sarcoma
HIV 
60.1 13.0 65.7 14.2
as.e.: standard error.
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lower in Uganda than in the United States for almost all forms of
cancers. The only exceptions were patients with prostate cancer
and thyroid cancer, who had similar median ages. Data of patients
with eye cancer are not comparable, as almost all black American
patients included in the data set had retinoblastoma, a childhood
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Figure 1 5-year relative survival (in %) of cancer patients in Kampala, Uganda and in the United States (SEER, Black Americans), 1993–1997.
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from squamous cell carcinoma of the conjunctiva. We provide
separate median ages for HIV-positive and HIV-negative Ugandan
Kaposi sarcoma patients. As a result of the difference in the nature
of eye cancers present in the Ugandan and American populations
and the lack of information on HIV status of American patients
with Kaposi sarcoma, no comparative analysis is provided for
these two cancers.
Table 3 presents the absolute and relative survival estimates for
the Ugandan cancer patient populations. The prognosis of
Ugandan cancer patients was generally very poor. The lowest
survival was recorded for patients with nasopharyngeal, stomach
,or lung cancer, none of whom survived 5 years. Patients with
other gastrointestinal tract cancers also had very low survival. The
highest survival figures were seen for HIV-negative Kaposi
sarcoma patients, and for patients with breast cancer or prostate
cancer: the 5-year relative survival of these patients was 65.7, 45.4,
and 46.9%, respectively.
Figure 1 shows the 5-year relative survival curves of the
Ugandan patients compared to the age-adjusted curves of black
American patients. The most dramatic difference was seen among
patients with thyroid cancer, who can be cured today in the United
States in almost every case: 95% of the patients survived the first
year after diagnosis, after which no excess mortality due to the
cancer was experienced. In contrast, Ugandan patients experienced
excess mortality over the entire follow-up period, and the relative
survival was 12% 5 years after the diagnosis. In general, the relative
survival curves of patients with small chances of cure even in
developed countries, such as oesophageal, stomach, liver, and lung
cancer, are very similar in the two patient groups. Patients with
cancers that have more promising treatment regimens or where
screening and early diagnosis is possible have much better survival
in the United States. In particular, very large survival disadvan-
tages of Ugandan patients were apparent for nasopharyngeal,
colorectal, cervical, ovarian, and prostate cancer.
DISCUSSION
The prognosis of patients in this Ugandan study population was
very poor, and much lower for almost all forms of cancer than the
prognosis of patients in the United States or other developed
countries. These survival figures are even lower than most
previously published survival estimates from other developing
countries (Sankaranarayanan et al, 1998). In particular, Ugandan
patients with nasopharyngeal, colorectal, ovarian, and thyroid
cancer experience much lower survival than patients in other, non-
African developing countries. The very low survival estimates for
patients with oesophageal, stomach, liver, and lung cancer are
similar to those observed in other developing countries, but
survival from these cancers is generally poor all over the world. The
survival of patients with breast or prostate cancer and lymphomas
was similar to that observed in other developing countries.
Although shocking, these survival estimates are unfortunately
not surprising. Uganda is a very poor country: annual per capita
health expenditure is currently estimated at only 36 dollars
(WHOSIS, 2000), and 40% of the population live in absolute
poverty (living on less than 1$ a day and unable to afford enough
food to consume 2000–3000 calories a day) (Kikule, 2003). Given
the constraints posed by the limited resources, the availability of
cancer care may depend on the patient’s financial contribution. At
the same time, there is a lack of resources at every level of cancer
care. In 1998, there were only two radiotherapy units and one
chemotherapy unit in the country, and only an estimated 5% of
patients had access to these facilities. Further constraints are posed
by the lack of medical personnel: in Kampala, there are only
approximately 50 doctors per 100000 people (USA: 279) (WHOSIS,
1998; Merriman, 1999; Merriman and Heller, 2002). In 1993, a
hospice service was started in Kampala to provide mainly home
based palliative care for cancer and AIDS patients. The hospice
services, which are never refused if a patient is unable to
contribute to the cost of the service (Merriman and Heller,
2002), are probably the most widely utilised cancer services in the
study area. The hospice service, which provided 20% of the vital
status information in this study, is a great success and functions as
a model for other African countries wishing to set up a patient-
oriented hospice service (Merriman and Heller, 2002).
Completeness and accuracy of the data are always of concern in
registry studies of survival, and particularly so in those from
developing countries (Sankaranarayanan et al, 1998). In Kampala,
the collection of follow-up data was particularly challenging and
difficult, as described in detail in the methods section. As a result,
a large proportion of patients could not be included or were lost to
follow-up before study closure. This gives rise to concern that the
survival estimates may be biased. However, although the vital
status of lost-to-follow-up patients is unknown, the study
personnel managed on many occasions to acquire some informa-
tion about these patients from different sources, such as
neighbours, landlords, etc. According to these notes, many of
them went ‘up-country’, most probably back to their own
community. The fact that these patients were not recorded at
any health institution means that they are most probably not
getting any treatment because specialised treatment is not available
outside Kampala. Furthermore, it has been documented that in the
Ugandan context patients prefer to be at home and be cared for by
their families when they are ill. Patients are usually discharged
from the hospital when they can not be helped any more, and they
prefer to go home as people are customarily buried in their family
village when they die (Kikule, 2003). It is therefore unlikely that
patients who were lost-to-follow-up had had a much higher
survival than patients with completed follow-up. Furthermore, the
effect of loss to follow-up on population-based survival estimates
in developing county settings has been previously assessed and
was found to be marginal, even when lost to follow-up proportions
were high (30–40%) and nonrandom with regard to prognostic
factors (Swaminathan et al, 2002; Sriamporn et al, 2004). There-
fore, it is reasonable to suppose that despite considerable exclusion
and lost to follow-up, our results are free from a meaningful bias
and adequately reflect the true survival experience of cancer
patients in Uganda.
Stage is often considered to be the most important factor
determining survival. Unfortunately, only sporadic information
was available on this factor in our data set. However, it is
commonly believed that stage at diagnosis is advanced in Africa
for many cancers (Parkin et al, 2003), and as screening and
education programmes are almost nonexistent, there is little
reason to believe that this observation is not correct. Given that
more than 60% of deaths occurred within the first year after
diagnosis, and about 80% of deaths occurred within the first 2
years after diagnosis in this study population, it seems reasonable
to assume that many of these patients were only diagnosed very
late, when effective treatment is rarely possible.
In conclusion, the survival of cancer patients in Uganda is very
poor and in its totality worse than that was reported from other
non-African developing countries. Despite the challenging context
and the discussed limitations, we are convinced that the data
collected and the results are consistent with the described health
care realities and accurately reflect the state of cancer management
in Uganda today. Cancer management faces an enormous task in
the country, and should be focused on those cancers, which pose
the largest burden on the population, that may be prevented, or
screened for comparatively easily, and for which deliverable
treatment promises with positive outcome.
On the policy level, the results underscore the importance of the
consistent application of the national cancer control programme
guidelines as outlined by the WHO (WHO, 2002). In addition,
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the very successful hospice services, particularly in the rural areas
of the country.
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